NEW YORK--(BUSINESS WIRE)-- , une marque de Dassault Systèmes et leader des solutions d’essais cliniques pour l’industrie des sciences de la vie, a été désignée comme leader dans la première évaluation PEAK Matrix ® des systèmes de gestion des essais cliniques réalisée par Everest Group en 2024. Ce rapport analyse 13 fournisseurs sur la base de l’impact de leurs produits sur le marché ainsi que de leur capacité à offrir des solutions performantes et de qualité. se distingue dans l’industrie en fournissant des données patient transparentes et en temps réel, révolutionnant ainsi le suivi des ...
>Ramp-up in the expansion of Medidata’s solutions portfolio - This week Medidata is holding its annual commercial conference, Medidata Next in New York, with the inaugural keynote speech taking place yesterday (main speakers: CEO of Medidata Anthony Costello, appointed in March, the CTO of Medidata, as well as Bernard Charlès, Executive Chairman and Tarek Sherif, the co-founder of Medidata and now chairman of the Lifescience vertical). The company then organised a ser...
>Accélération de l’expansion du portefeuille de solutions de Medidata - Medidata tient cette semaine sa conférence commerciale annuelle, Medidata Next à New York, avec une keynote inaugurale tenue hier (principaux speakers : le CEO de Medidata Anthony Costello, nommé en mars dernier, le CTO de Medidata, ainsi que Bernard Charlès, Executive Chairman et Tarek Sherif co-fondateur de Medidata, désormais Chairman du vertical Lifescience). La société a ensuite organisé une ...
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- (Euronext Paris: FR0014003TT8, DSY.PA) today announced that has chosen to deploy Dassault Systèmes’ 3DEXPERIENCE platform within its engineering processes for vehicle development. This press release features multimedia. View the full release here: Copyright © Volvo Car Corporation With an automotive industry constantly evolving toward electric, connected and autonomous mobility, companies must be able to accelerate the launch of advanced solutions. The 3DEXPERIENCE platform helps automotive manufacturers streamline enterprise-wide collaboration...
NEW YORK--(BUSINESS WIRE)-- , a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant...
NEW YORK--(BUSINESS WIRE)-- , a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, is kicking off , its premier life sciences conference. Uniting more than 1,000 healthcare customers and partners, the event will showcase AI-powered innovations that accelerate clinical trials, streamline data management, and enhance decision-making for life-saving therapies. At the event, Medidata will unveil three experiences centered on the full ecosystem of clinical trials—data management, patient engagement, and study coordination—providing tools that streamline ...
NEW YORK--(BUSINESS WIRE)-- , une marque de Dassault Systèmes et principal fournisseur de solutions d'essais cliniques pour l'industrie des sciences du vivant, a lancé deux nouvelles offres groupées pour répondre aux demandes croissantes de la recherche en oncologie et en vaccinologie. et renforcent les directives de la FDA concernant les critères d'évaluation centrés sur le patient, les conceptions d'essais adaptatifs et la diversité des essais. En unifiant les principaux éléments des essais, tels que les résultats rapportés par les patients en temps réel et la gestion de l'imagerie, ces so...
NEW YORK--(BUSINESS WIRE)-- , une marque de Dassault Systèmes et le principal fournisseur de solutions d’essais cliniques pour l’industrie des sciences de la vie, a annoncé aujourd’hui un partenariat avec , leader des solutions neuroscientifiques, afin de remodeler les essais cliniques et la mesure des résultats pour les maladies du système nerveux central (SNC), notamment les maladies neurodégénératives, psychiatriques, motrices et les troubles rares du développement neurologique. Ensemble, les deux entreprises offriront une expérience améliorée, soutenue par (évaluation électronique des ré...
NEW YORK--(BUSINESS WIRE)-- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. and reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy ...
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- (Euronext Paris: FR0014003TT8, DSY.PA) today announced the availability of the world’s first guide for the medical device industry that outlines how to use virtual twins to accelerate clinical trials. This guide was published following the successful completion of a five-year collaboration with the U.S. Food and Drug Administration. The in silico clinical trial “ENRICHMENT Playbook” marks a significant advancement in the integration of virtual twins into the regulatory process in response to needs for improved patient safety, regulatory complianc...
NEW YORK--(BUSINESS WIRE)-- , a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. Together, the companies will deliver an improved experience, supported by (electronic clinical outcome assessment) that empowers customers through faster trial starts and optimal rater experiences. T...
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- (Euronext Paris: FR0014003TT8, DSY.PA) today announced that the 3DEXPERIENCE platform is now listed as a PACT conformant solution by the World Business Council for Sustainable Development , the global standard for calculating and exchanging Scope 3 greenhouse gas data across the value chain. This recognition helps Dassault Systèmes’ customers and their value chains make smart, carbon-informed business decisions to deliver on climate commitments and reach net zero. Dassault Systèmes is supporting its customers as part of a growing ecosystem striv...
Following last week's earnings release, we take a step back and proceed to review our investment case, by analysing one by one the issues that Dassault Systèmes has been facing and that led to its derating. We reach the conclusion that these setbacks are for the most part, both short-term and secto
>Automobile sector hurts Q3 growth… - Yesterday morning Dassault Systèmes reported Software sales growth of +3% yoy at cc, in the low end of its guidance range (3% to 6% at cc) primarily due to contract postponements in the automobile sector, as customers have to revise their budgets due to much lower-than-expected vehicle sales. Elsewhere, Dassault Systèmes posted satisfactory performances with: 1/ other Industrial Innovation segments, especially aerospace & defense,...
>Le secteur automobile pénalise la croissance du T3… - Hier matin Dassault Systèmes a publié une croissance Software de +3% y/y cc, en bas de fourchette de sa guidance (3% à 6% cc) essentiellement en raison de décalages de contrats observés dans le secteur automobile, alors que les clients sont contraints de revoir leurs budgets suite à des ventes de véhicules nettement inférieures aux attentes. Pour le reste, Dassault Systèmes affiche des performances satisfaisantes,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.